Add like
Add dislike
Add to saved papers

DEVELOPMENT AND VALIDATION OF A NOVEL TOOL TO PREDICT HOSPITAL READMISSION RISK AMONG PATIENTS WITH DIABETES.

Endocrine Practice 2016 July 14
OBJECTIVE: To develop and validate a tool to predict the risk of all-cause readmission within 30 days (30d readmission) among hospitalized patients with diabetes.

METHODS: A cohort of 44,203 discharges was retrospectively selected from the electronic records of adult patients with diabetes hospitalized at an urban academic medical center. Discharges of 60% of the patients (n=26,402) were randomly selected as a training sample to develop the index. The remaining 40% (n=17,801) were selected as a validation sample. Multivariable logistic regression with generalized estimating equations was used to develop the Diabetes Early Readmission Risk Indicator (DERRI(TM)).

RESULTS: Ten statistically significant predictors were identified: employment status, living within 5 miles of the hospital, pre-admission insulin use, burden of macrovascular diabetes complications, admission serum hematocrit, creatinine, and sodium, having a hospital discharge within 90 days before admission, most recent discharge status up to 1 year before admission, and a diagnosis of anemia. Discrimination of the model was acceptable (C-statistic 0.70), and calibration was good. Characteristics of the validation and training samples were similar. Performance of the DERRI(TM) in the validation sample was essentially unchanged (C-statistic 0.69). Predicted 30d readmission risk was also similar between the training and validation samples (39.3% and 38.7% in the highest quintiles).

CONCLUSION: The DERRI(TM) was found to be a valid tool to predict all-cause 30d readmission risk of individual patients with diabetes. The identification of high-risk patients may encourage the use of interventions targeting those at greatest risk, potentially leading to better outcomes and lower healthcare costs.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app